A groundbreaking medication is now available through the NHS to assist individuals with multiple sclerosis (MS) in enhancing their ability to walk. Termed fampridine, this “life-changing” drug benefits patients by acting as a “signal booster” for nerves damaged by MS, facilitating more efficient transmission of electrical messages to the muscles.
Approximately 5,000 patients in England are set to receive this twice-daily pill, a significant advancement from the previous treatment options limited to physiotherapy, walking aids, or foot support devices. Ceri Smith, the MS Society’s head of policy and evidence, expressed delight in the NHS’s approval of fampridine, highlighting its positive impact on individuals living with MS.
MS, an autoimmune disease affecting the brain and spinal cord, presents varied symptoms such as fatigue, dizziness, tingling sensations, muscle cramps, visual impairments, and memory issues. Fampridine, priced at about £4,700 per patient annually, has undergone negotiation for a discounted rate by the NHS due to its collective bargaining power.
Professor Frankie Swords, the NHS national medical director, emphasized the transformative potential of fampridine in alleviating walking difficulties faced by patients with MS. The medication enhances nerve signal transmission, enabling easier walking and increased mobility for daily activities, ultimately promoting greater independence for individuals.
Patients diagnosed with MS are evaluated based on their disability level, with those scoring between four and seven on the disability scale being eligible for fampridine treatment. Trials of fampridine showcased promising outcomes, with 43% of patients experiencing improved walking speed and endurance.
Aysen Slack, a 65-year-old from Eastbourne, shared her positive experience with fampridine, noting its efficacy in improving her mobility. Despite discontinuing the medication previously due to financial constraints, she expressed interest in trying fampridine through the NHS, highlighting the significant impact it could have on enhancing her walking abilities and overall quality of life.
Ceri Smith stressed the importance of ensuring widespread access to fampridine across MS services, emphasizing the need for support in making this beneficial medication available to all individuals with MS throughout England.
